Tirzepatide and the Dual-Incretin Era

For a while, the obesity-medicine story had one main character. GLP-1 was the gut hormone everyone copied, and the drugs built around it rewrote what was possible. Then a second hormone walked back onto the stage — one that had spent decades being written off as a disappointment — and the field tilted again. Tirzepatide acts on two incretin receptors instead of one, and the trial numbers that followed were large enough to make "dual incretin" the phrase of the moment.

It is worth understanding what that phrase means and, just as importantly, what it does not. The temptation is to read the field as a ladder where each newer drug is simply better than the last for everyone. The biology is more interesting than that, and the clinical reality is less tidy.

The hormone that came in from the cold

The first incretin ever discovered was not GLP-1 but GIP — glucose-dependent insulinotropic polypeptide. For years GIP was the unpromising sibling. On its own, in people with type 2 diabetes, it seemed to do little useful, and attention drifted to GLP-1, which delivered.

Tirzepatide revived the idea by combining both. It is a single molecule that activates the GLP-1 receptor and the GIP receptor at the same time. The working theory is that, against a background of GLP-1 activity, GIP turns out to be a useful partner after all — contributing to appetite regulation and metabolic effects in a way it could not manage alone. Exactly why the combination outperforms either hormone individually is still being worked out; the receptors sit in overlapping but not identical places in the brain and body, and the interplay is an active research question rather than a settled story. What is clear is that hitting two incretin pathways at once produces effects that single-receptor drugs do not.

What the trials showed

The headline results came from two trial programmes. SURMOUNT-1 studied tirzepatide for weight management in people with obesity but without diabetes. Average weight loss at the higher doses, over roughly a year and a half and alongside lifestyle support, reached into the low-to-mid twenties as a percentage of body weight — figures that pushed the conversation into territory previously associated mainly with surgery. The SURPASS programme studied the same drug in type 2 diabetes and showed large reductions in HbA1c, the long-term blood-glucose marker, along with weight loss.

These numbers deserve the same handling as any trial result. They are averages, with wide individual variation around them. They were achieved with structured dietary and activity support, not the drug in isolation. The participants were selected and closely supervised. And impressive average weight loss is a meaningful outcome, but the outcomes that matter most in the long run — heart attacks, strokes, deaths, years of healthy life — are measured over far longer horizons, and that evidence accumulates more slowly than the weight-loss headlines. The early results are genuinely striking. They are not the same as decades of outcome data, and an honest account keeps the two apart.

Why this isn't a simple league table

It is natural to line the drugs up by average weight loss and crown a winner. Clinically, that is the wrong instrument. The right medicine for a given person is not the one with the biggest number in a trial; it is the one that fits their particular situation.

Several things vary between these medicines and between the people taking them. What is the treatment actually for — obesity, type 2 diabetes, or both? What other conditions and other medicines are in play? How well does the individual tolerate the gradual dose escalation, given that gut side effects are common across the whole class? What is licensed, available and affordable in their setting? And what matters to that person about how a medicine fits their life? A drug with a slightly higher average effect that someone cannot tolerate is worse, for them, than a drug they can. This is the reason the choice belongs in a consultation with a prescriber who knows the person's full history, not in a ranking table — and the reason "the strongest one" is not a meaningful answer to "which should I take".

Same class, same caveats

Adding a second incretin did not abolish the limitations of the first. Tirzepatide carries the same broad profile of considerations as the rest of the class. Gut side effects — nausea, vomiting, diarrhoea, constipation — are common, particularly early and after dose increases. The serious-but-rarer signals around gallbladder disease and pancreatitis apply. There are specific contraindications, including a history of certain rare thyroid cancers, and it is not used in pregnancy. And the pattern of weight regain after stopping, seen clearly with semaglutide in the STEP 1 extension, reflects the same underlying reality: this is long-term treatment of a chronic condition, and withdrawing the treatment tends to let the condition reassert itself.

The dual-incretin design changes the size of some effects. It does not change the fundamental framing. These remain medicines for a chronic condition, used under supervision, with real benefits and real boundaries.

The access problem, again

Everything written in this section about sourcing applies with full force here. High demand and intense publicity create exactly the conditions in which a grey market thrives: unlicensed products, home-mixed vials, and counterfeit pens. The MHRA has warned specifically about falsified weight-loss injections, some found to contain the wrong substance or an unknown dose. A newer, more talked-about drug is, if anything, a more attractive target for counterfeiters, not a safer one.

The principle does not change with the molecule. A licensed medicine means a known dose, a regulated supply chain, a prescriber who assessed suitability, and a system that monitors harm. The route that has all of those runs through a regulated prescriber and a registered pharmacy. The route that has none of them is a gamble with a vial.

Practical takeaways

• Tirzepatide acts on two incretin receptors — GLP-1 and GIP — rather than one, and GIP turns out to be a useful partner that it never was alone.
• SURMOUNT-1 and SURPASS showed large average weight loss and blood-glucose improvement, but as averages, with lifestyle support, over limited time horizons.
• "Dual incretin" is not a guarantee that newer means better for any given person — the right choice depends on the individual's full picture.
• The class-wide caveats still apply: gut side effects, rarer serious signals, contraindications, and weight regain after stopping.
• Counterfeit and unlicensed products are a real danger; a regulated prescriber and registered pharmacy are the safe route.

What this doesn't mean

It does not mean tirzepatide is the right treatment for everyone, or that bigger trial numbers translate into the best outcome for any specific person. Nor does the dual-incretin label imply a finished science — much of how and why it works, and its long-term outcome data, is still being established.

When to seek medical advice

Decisions about whether any weight-loss or diabetes medicine is appropriate belong with a qualified prescriber who can assess your full medical history. If you are taking one of these medicines and develop severe, persistent abdominal pain, repeated vomiting, signs of dehydration, or any symptom that worries you, seek medical advice promptly.

A closing thought

The most quietly remarkable part of the tirzepatide story is that the breakthrough came from a hormone everyone had given up on. GIP spent years labelled a failure, until someone tried it in the right company. It is a useful reminder about medicine generally: progress rarely arrives as a single hero molecule, and the next advance is at least as likely to come from reconsidering something old as from inventing something new.

Further reading and sources

• NICE TA1026 — technology appraisal on tirzepatide for managing overweight and obesity
• MHRA — warnings on falsified weight-loss injections and unregulated sources
• SURMOUNT-1 — randomised trial of tirzepatide for weight management
• SURPASS programme — tirzepatide trials in type 2 diabetes
• Endocrine Society — clinical guidance on the pharmacological management of obesity

Brand names are mentioned for identification only. The author has no commercial relationship with any manufacturer, and nothing here is an advertisement for, or recommendation to obtain, any medicine.